The Eating Disorders Genetics Initiative (EDGI): study protocol
- PMID: 33947359
- PMCID: PMC8097919
- DOI: 10.1186/s12888-021-03212-3
The Eating Disorders Genetics Initiative (EDGI): study protocol
Abstract
Background: The Eating Disorders Genetics Initiative (EDGI) is an international investigation exploring the role of genes and environment in anorexia nervosa, bulimia nervosa, and binge-eating disorder.
Methods: A total of 14,500 individuals with eating disorders and 1500 controls will be included from the United States (US), Australia (AU), New Zealand (NZ), and Denmark (DK). In the US, AU, and NZ, participants will complete comprehensive online phenotyping and will submit a saliva sample for genotyping. In DK, individuals with eating disorders will be identified by the National Patient Register, and genotyping will occur using bloodspots archived from birth. A genome-wide association study will be conducted within EDGI and via meta-analysis with other data from the Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED).
Discussion: EDGI represents the largest genetic study of eating disorders ever to be conducted and is designed to rapidly advance the study of the genetics of the three major eating disorders (anorexia nervosa, bulimia nervosa, and binge-eating disorder). We will explicate the genetic architecture of eating disorders relative to each other and to other psychiatric and metabolic disorders and traits. Our goal is for EDGI to deliver "actionable" findings that can be transformed into clinically meaningful insights.
Trial registration: EDGI is a registered clinical trial: clinicaltrials.gov NCT04378101 .
Keywords: Anorexia nervosa; Binge-eating disorder; Bulimia nervosa; Eating disorders; Genome-wide association; Psychiatric genetics; Psychiatric genomics consortium; Social media.
Conflict of interest statement
C.M. Bulik: Shire (grant recipient, Scientific Advisory Board member); Idorsia (consultant); Pearson (author, royalty recipient).
L.M. Thornton: no competing interests to declare.
R. Parker: no competing interests to declare.
H. Kennedy: no competing interests to declare.
C. MacDermod: no competing interests to declare.
J. Guintivano: no competing interests to declare.
L. Cleland: no competing interests to declare.
A.L. Miller: no competing interests to declare.
L.E. Harper: no competing interests to declare.
J.T. Larsen: no competing interests to declare.
Z. Yilmaz: no competing interests to declare.
J. Grove: no competing interests to declare.
P.F. Sullivan reports: Lundbeck (advisory committee, grant recipient), RBNC Therapeutics (advisory committee, shareholder).
L.V. Petersen: no competing interests to declare.
J. Jordan: no competing interests to declare.
M. Kennedy: no competing interests to declare.
N.G. Martin: no competing interests to declare.
References
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
